Arvinas Holding Company (ARVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jeet ...

Check the time stamp on this data. Updated AI-Generated Signals for Arvinas Inc. (ARVN) available here: ARVN. Type a few ...

Arvinas (ARVN) shares fell 5.7% in recent Friday trading after the company outlined plans for a data – Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor ...

Arvinas Holding Company (ARVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...

In this article, we are going to take a look at where Arvinas, Inc. (NASDAQ:ARVN) stands against the other small-cap biotech stocks. The biotechnology sector is expanding quickly due to rising ...

These sales were part of a planned sell-to-cover transaction to satisfy tax obligations related to the vesting and settlement of certain Restricted Stock Units (RSUs). Following these transactions, ...

In trading on Thursday, shares of Arvinas Inc (Symbol: ARVN) entered into oversold territory, hitting an RSI reading of 28.8, after changing hands as low as $17.85 per share. By comparison ...

Investors in Arvinas Inc (Symbol: ARVN) saw new options become available today, for the March 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay ...

ARVN stock opened at $19.50 on Thursday. Arvinas has a 52 week low of $18.51 and a 52 week high of $53.08. The company has a market cap of $1.34 billion, a P/E ratio of -4.18 and a beta of 1.82 ...

Arvinas-Pfizer Partner Cancer Drug Trial Shows 63% Clinical Benefit In Breast Cancer Patients Arvinas and Pfizer share Phase 1b TACTIVE-U trial results showing 62.5% clinical benefit rate and ...

Nov. 27, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that ...